-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, D4oYsnZHHlMqjrusywbLfLQPEQTuYn49q0xPhn/wuRyP3qMsVzZjcBH8Ds9iljPG uaVcMIQKX4kl9IR2GXpItQ== 0000898430-97-001829.txt : 19970502 0000898430-97-001829.hdr.sgml : 19970502 ACCESSION NUMBER: 0000898430-97-001829 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 19970421 ITEM INFORMATION: Other events ITEM INFORMATION: Financial statements and exhibits FILED AS OF DATE: 19970501 SROS: NASD FILER: COMPANY DATA: COMPANY CONFORMED NAME: OXIS INTERNATIONAL INC CENTRAL INDEX KEY: 0000109657 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 941620407 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-08092 FILM NUMBER: 97593371 BUSINESS ADDRESS: STREET 1: 6040 N CUTTER CIRCLE STE 317 CITY: PORTLAND STATE: OR ZIP: 97217 BUSINESS PHONE: 5032833911 MAIL ADDRESS: STREET 1: 6040 N CUTTER CIRCLE STE 317 CITY: PORTLAND STATE: OR ZIP: 97217 FORMER COMPANY: FORMER CONFORMED NAME: DDI PHARMACEUTICALS INC DATE OF NAME CHANGE: 19920703 FORMER COMPANY: FORMER CONFORMED NAME: DIAGNOSTIC DATA INC /DE/ DATE OF NAME CHANGE: 19850312 8-K 1 FORM 8-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ------------ FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported) April 21, 1997 -------------------------- OXIS INTERNATIONAL, INC. -------------------------------------------------- (Exact Name of Registrant as Specified in Charter) DELAWARE 0-8092 94-1620407 - -------------------------------------------------------------------------------- (STATE OR OTHER (COMMISSION FILE NUMBER) (IRS EMPLOYER JURISDICTION OF IDENTIFICATION NUMBER) INCORPORATION) 6040 N. Cutter Circle, Suite 317, Portland, OR 97217 - -------------------------------------------------------------------------------- (ADDRESS OF PRINCIPAL EXECUTIVE OFFICES) (ZIP CODE) Registrant's telephone number, including area code. (503) 283-3911 ----------------------------- - -------------------------------------------------------------------------------- (FORMER NAME OR FORMER ADDRESS, IF CHANGED SINCE LAST REPORT) Exhibit Index at page: 5 --- ITEM 5. OTHER EVENTS (a) On April 21, 1997, OXIS International, Inc. (the "Company") announced that the French Commission des Operations de Bourse issued a visa allowing the Company to present its preliminary prospectus to raise capital through an underwritten public offering of its Common Stock in France. The offering is scheduled to commence on April 22, 1997 and will culminate in the listing of the Company's Common Stock on the newly opened French Stock Market, Le Nouveau Marche, on May 6, 1997. Upon such listing, the Company will be the first NASDAQ listed U.S. company quoted on Le Nouveau Marche, a Paris based stock exchange specifically designed to meet the needs of emerging growth companies. All of the securities mentioned herein have not been registered under the Securities Act of 1933, as amended. The foregoing securities may not be offered or sold in the United States. A copy of the press release with respect to the issuance of the visa referenced above and the listing of the Company's Common Stock on Le Nouveau Marche is attached as an exhibit to this report. Certain of the statements made in this report and in the attached press release are forward looking statements that are based on current expectations which involve a number of uncertainties, including the Company's ability to enter the Le Nouveau Marche stock market and consummate the French public offering. The events described herein may not occur in a timely manner, or at all. Accordingly, the Company's future activities may differ materially from those projected in the forward-looking statements. - 2 - ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS ------------------------------------------------------------------ (c) Exhibits 99.1 Press Release, dated April 21, 1997 - 3 - SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. OXIS INTERNATIONAL, INC. (Registrant) Dated: April 29, 1997 By: /s/ Jon S. Pitcher ------------------------ Name: Jon S. Pitcher Title: Chief Financial Officer and Vice President - 4 - EXHIBIT INDEX Exhibit No. Description ----------- ----------- 99.1 Press Release dated April 21, 1997. - 5 - EX-99.1 2 PRESS RELEASE DATED 04/21/97 EXHIBIT 99.1 OXIS International announces French COB approval and schedule of Nouveau Marche public offering - FIRST NASDAQ U.S. COMPANY TO BE LISTED ON THE FRENCH STOCK MARKET, LE NOUVEAU MARCHE - PARIS--(BUSINESS WIRE)--April 21, 1997--OXIS International, Inc. (NASDAQ: OXIS) announced today that the French Commission des Operations de Bourse issued a visa allowing OXIS to present its preliminary prospectus to raise capital through an underwritten public offering of its common stock in the European marketplace. The offering is scheduled to commence on April 22, 1997, and will culminate in the listing of OXIS' common stock on the French Stock Market, Le Nouveau Marche, on May 6, 1997. Upon admission, OXIS will be the first NASDAQ-listed U.S. company quoted on Le Nouveau Marche, a Paris-based stock exchange specifically designed to meet the needs of emerging growth companies. Earlier this week, a press conference was held to introduce OXIS to a group of interested French journalists. "The offering proceeds should allow us to advance our lead therapeutic molecule BXT-51072 into Phase II Clinical Trials and initiate Phase I studies in our lead molecule, TX-153, from our series of lipid soluble antioxidants," stated OXIS Chairman Ray R. Rogers. OXIS International, Inc. is a drug discovery and diagnostics company focused on the development of novel therapeutic molecules and supportive technologies to treat diseases associated with damage from free radicals and reactive oxygen species (ROS), i.e., diseases of oxidative stress. OXIS' lead therapeutic molecule, BXT-51072, is a glutathione peroxidase mimic that completed Phase I trials and for which OXIS filed an IND for inflammatory bowel diseases in 1996. A second advanced molecule, TX-153, is a lipid soluble antioxidant that protects cell membranes from damage from free radicals and ROS. OXIS is headquartered in Portland, Oregon, with a French subsidiary, OXIS International, S.A., located outside of Paris. All securities mentioned in this press release have not been, and will not be, registered under the Securities Act of 1933, as amended. The foregoing securities may not be offered and sold in the United States, absent registration under the Securities Act or an applicable exemption from such registration requirements. Certain of the statements contained in this press release are forward-looking statements that are based on current expectations which involve a number of uncertainties, including the Company's ability to enter the Le Nouveau Marche stock market and consummate the French public offering. The events described herein may not occur in a timely manner, or at all. Accordingly, the Company's future activities may differ materially from those projected in the forward-looking statements. CONTACT: OXIS International, Inc. or KVO Mike DeMello Will Anderson 800/547-3686 503/221-2351 will-anderson@kvo.com -----END PRIVACY-ENHANCED MESSAGE-----